<DOC>
	<DOCNO>NCT00767416</DOCNO>
	<brief_summary>The primary objective study describe 28-day post-final dose safety tolerability three dose MEDI-559 10^5 FFU administer healthy RSV seronegative child 1 &lt; 24 month age .</brief_summary>
	<brief_title>A Randomized , Double-Blind , Placebo-Controlled Study Evaluate Safety MEDI-559 Healthy 1 &lt; 24 Month-Old Children</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , multi-dose , Phase 1/2a multi-center trial evaluate safety , tolerability , viral shedding , immunogenicity , genotypic phenotypic stability MEDI-559 RSV seronegative infant 5 &lt; 24 month age infants 1 &lt; 3 month age regardless baseline serostatus . The primary objective study describe 28-day post-final dose safety tolerability three dose MEDI-559 10^5 FFU administer healthy RSV seronegative child 5 &lt; 24 month age healthy infant 1 &lt; 3 month age regardless baseline serostatus . MEDI-559 administer dose 10^5 fluorescent focus unit ( FFU ) 0 , 2 , 4 month schedule two cohort subject step-wise fashion . The target sample size study 320 subject , 160 subject 5 &lt; 24 month age enrol Cohort 1 160 subject 1 &lt; 3 month age enrol Cohort 2 . Each cohort randomize 1:1 ( MEDI-559 placebo ) stratify site . Cohort 1 initiate dose 10^5 FFU MEDI-559 . Blinded safety data first 40 subject enrol Cohort 1 28 day follow administration first dose vaccine review . If safety concern note , Cohort 2 initiate dose 10^5 FFU . Enrollment Cohort 2 halt approximately 40 subject randomize , blind safety data review 28 day post Dose 1 . If safety concern note , remainder Cohort 2 enrol . All subject follow 365 day randomization ensure subject follow RSV season .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female whose age day randomization fall within one two age cohort : Cohort 1 : 5 &lt; 24 month ( reach 5th month birthday yet reach 2nd year birthday ) ; Cohort 2 : 1 &lt; 3 month ( &gt; 28 day age yet reach 3rd month birthday ) Cohort 1 : Subject seronegative RSV screening Subject product normal full term pregnancy ( defined 3642 week gestation ) Subject general good health Written inform consent HIPAA authorization ( applicable ) obtain subject 's legal representative Subject 's legal representative willing able bring subject study site evaluation respiratory illness accordance protocol Any fever ( ≥ 100.4°F [ ≥ 38.0°C ] ) , regardless route within 7 day prior randomization Acute illness ( define presence moderate severe sign symptom ) time randomization Moderate severe nasal congestion investigator 's opinion could prevent intranasal delivery vaccine Cohort 1 : weight ≤ 5th percentile age day randomization Cohort 2 : history low birth weight ( ie , &lt; 2500 gram birth ) weight ≤ 5th percentile age day randomization Living home enrol classroom day care infant &lt; 6 month age within 28 day dose ( one child per household may enrol study ) Contact pregnant caregiver within 28 day dose Living household someone immunocompromised within 28 day dose ; subject also avoid close contact immunocompromised individual least 28 day study vaccine dose Living household someone work healthcare field direct patient care responsibility within 28 day dose Living household someone day care provider preschool teacher child &lt; 6 month age within 28 day dose</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>23 Months</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>MEDI-559</keyword>
	<keyword>Respiratory Syncytial Virus</keyword>
	<keyword>RSV</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Vaccine</keyword>
	<keyword>respiratory syncytial virus , RSV , pediatric , vaccine</keyword>
</DOC>